Nalaganje...
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature
The current evidence regarding immunotherapy plus targeted therapy in esophageal neuroendocrine carcinoma (NEC) is lacking. Camrelizumab is a programmed cell death protein 1 inhibitor. Apatinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. A 50-year-old f...
Shranjeno v:
| izdano v: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678944/ https://ncbi.nlm.nih.gov/pubmed/33092443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1829265 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|